Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus

Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus

Objectives Numerous case reports have referred to new onset or flare of SLE after SARS-CoV-2 messenger RNA (mRNA) vaccines. Several observational studies showed that the short-term flare rate of SLE after SARS-CoV-2 vaccination is low. However, well-controlled clinical surveys are unavailable and th...

Full description

Bibliographic Details
Main Authors: Akira Onishi, Hideaki Tsuji, Shuji Akizuki, Masao Tanaka, Ryosuke Hiwa, Ran Nakashima, Hajime Yoshifuji, Tsuneyasu Yoshida, Yudai Takase, Mirei Shirakashi, Hideo Onizawa, Koji Kitagori, Akio Morinobu
Format: Article
Language:English
Published: BMJ Publishing Group 2022-08-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/9/1/e000727.full

Internet

https://lupus.bmj.com/content/9/1/e000727.full

Similar Items